Stock comparison
IDEXX Laboratories
PROCEPT BioRobotics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
PRCT
PROCEPT BioRobotics
Market cap
$1.65B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | PRCT | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 27F | IDXX |
| Benjamin Graham | 80A | 54D | IDXX |
| Philip Fisher | 75B | 52C | IDXX |
| Peter Lynch | 71B | 44D | IDXX |
| Joel Greenblatt | 83C | 0F | IDXX |
| Charlie Munger | 87A | 34F | IDXX |
| Terry Smith | 84A | 34F | IDXX |
Side-by-side metrics
| Metric | IDXX | PRCT |
|---|---|---|
| Market cap | $44.12B | $1.65B |
| P/E (TTM) | 39.0x | - |
| EV/EBIT | 31.6x | - |
| ROIC (TTM) | 40.66% | -25.75% |
| Gross margin | 62.05% | 62.98% |
| Net margin | 24.63% | -31.82% |
| Revenue CAGR 5y | 7.56% | 72.9% |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Net margin24.63%vs -31.82%+177%
- ROIC (TTM)40.66%vs -25.75%+163%
- Market cap$44.12Bvs $1.65B+96%
PRCT leads on
- EV/EBIT-vs 31.6x+139%
- P/E (TTM)-vs 39.0x+137%
- Revenue CAGR 5y72.9%vs 7.56%+90%
- Debt / Equity0.1xvs 0.7x+79%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.